Fogari R, Zoppi A, Derosa G, Lusardi P, Mugellini A, Lazzari P
Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Int J Clin Pharmacol Ther. 1995 Aug;33(8):453-6.
The aim of this study was to assess the effects of ketanserin on insulin resistance in nondiabetic hypertensive patients. Eleven nonobese, nondiabetic mild to moderate hypertensives (6 males, 5 females, aged 39-59 years), after a 4 week run-in period on placebo, were treated with ketanserin 40 mg twice daily for 12 weeks. Blood pressure (BP) (by standard mercury sphygmomanometer) and insulin sensitivity (by the euglycemic hyperinsulinemic clamp technique) were evaluated at the end of the placebo period and at the end of the treatment period. Ketanserin produced a significant decrease in BP (from 160 +/- 13/100 +/- 4 mmHg to 146 +/- 10/89 +/- 5 mmHg p < 0.01). The amounts of exogenous glucose required to hold glucose levels constant during clamp were not changed by ketanserin as compared to placebo 34.5 +/- 3.5 g vs 33.8 +/- 3.1 g). The rate of glucose infusion required during the last 60 minutes of the clamp, used as an indicator of insulin sensitivity, was not different before and after treatment (5.52 +/- 0.41 mg/min/ kg vs 5.21 +/- 0.39mg/min/kg). These results suggest that in nonobese, nondiabetic hypertensive patients ketanserin monotherapy is effective in reducing BP values without affecting insulin sensitivity.
本研究的目的是评估酮色林对非糖尿病高血压患者胰岛素抵抗的影响。11名非肥胖、非糖尿病的轻度至中度高血压患者（6名男性，5名女性，年龄39 - 59岁），在服用安慰剂4周的导入期后，接受每日两次40 mg酮色林治疗，为期12周。在安慰剂期结束时和治疗期结束时评估血压（BP）（使用标准汞柱血压计）和胰岛素敏感性（通过正常血糖高胰岛素钳夹技术）。酮色林使血压显著降低（从160±13/100±4 mmHg降至146±10/89±5 mmHg，p<0.01）。与安慰剂相比，在钳夹期间维持血糖水平恒定所需的外源性葡萄糖量未因酮色林而改变（34.5±3.5 g对33.8±3.1 g）。钳夹最后60分钟所需的葡萄糖输注速率用作胰岛素敏感性指标，治疗前后无差异（5.52±0.41 mg/min/kg对5.21±0.39 mg/min/kg）。这些结果表明，在非肥胖、非糖尿病高血压患者中，酮色林单一疗法可有效降低血压值，而不影响胰岛素敏感性。
